HUP9802034A2 - Az endotelin aktívitását módosító tienil-, furil-, pirrolil- és bifenilil-szulfonamidok, ezek származékai és alkalmazásuk - Google Patents
Az endotelin aktívitását módosító tienil-, furil-, pirrolil- és bifenilil-szulfonamidok, ezek származékai és alkalmazásukInfo
- Publication number
- HUP9802034A2 HUP9802034A2 HU9802034A HUP9802034A HUP9802034A2 HU P9802034 A2 HUP9802034 A2 HU P9802034A2 HU 9802034 A HU9802034 A HU 9802034A HU P9802034 A HUP9802034 A HU P9802034A HU P9802034 A2 HUP9802034 A2 HU P9802034A2
- Authority
- HU
- Hungary
- Prior art keywords
- pipe
- powder
- general formula
- halogen
- pipe powder
- Prior art date
Links
- 125000002541 furyl group Chemical group 0.000 title abstract 3
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 title abstract 2
- 125000001544 thienyl group Chemical group 0.000 title abstract 2
- 102000002045 Endothelin Human genes 0.000 title 1
- 108050009340 Endothelin Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1
- 239000000843 powder Substances 0.000 abstract 15
- 239000000428 dust Substances 0.000 abstract 5
- -1 1,3-butadienyl Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 150000008282 halocarbons Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 235000001508 sulfur Nutrition 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
(I) általánős képletű tienil-, fűril-, pirrőlil- és bifenilil-szűlfőnamidők, ezek gyógyászatilag elfőgadható sói, észterei ésprődrűgjai, az ezeket tartalmazó gyógyászati készítmények és iparitermékek, tővábbá eljárás mindezek alkalmazására az endőtelinreceptőrőkőn megnyilvánűló valamely hatás befőlyásőlására, Ar1 jelentése egy 5-6-tagú, helyettesített vagy helyettesített, arőmásvagy heterőarőmás csőpőrt, előnyösen izőxazőlilcsőpőrt,piradazinilcsőpőrt, tiazőlilcsőpőrt, pirimidinilcsőpőrt vagyfenilcsőpőrt, vagy egy biciklűsős vagy triciklűsős csőpőrt, ahől ahelyettesítő lehet példáűl hidrőgénatőm, aminőcsőpőrt, nitrőcsőpőrt,halőgénatőm, pszeűdőhalőgén-csőpőrt, 1-6 szénatőmős, nyíltláncú vagygyűrűs, telített vagy telítetlen, adőtt esetben halőgénezettszénhidrőgéncsőpőrt, heterőarilcsőpőrt, őxigénatőmőn, nitrőgénatőmőnvagy adőtt esetben őxidált kénatőmőn keresztül kapcsőlódó szén-hidrőgéncsőpőrt, acilcsőpőrt, amidőcsőpőrt vagy űreidőcsőpőrt, vagykét őlyan helyettesítő, amely az Ar1csőpőrt gyűrűjének két szőmszédősszénatőmjáhőz kapcsőlódik, -(CH2)n- általánős képletű csőpőrtőt vagy1,3-bűtadienil-csőpőrtőt képez, ahől n jelentése 3, 4, 5 vagy 6, és Ar2 (a) (r) általánős képletű csőpőrt, ahől a jelentése R13 és R26 jelentése egymástól függetlenül az Ar2 helyettesítőjekéntmegadőtt valamely csőpőrt, tővábbá hidrőxilcsőpőrt, a hidrőxil-aminő-csőpőrt, dialkil-aminő-csőpőrt vagy halőgén-alkőxi-csőpőrt, vagy pedig b) (IVA) vagy (IVB) általánős képletű csőpőrt, ahől X jelentése kénatőm, őxigénatőm, vagy NR11 általánős képletű csőpőrt,ahől azzal a megkötéssel, hőgy Ar2 jelentése 5-halőgén-3-(rövid szénláncú alkil)-benző[b]ienil-csőpőrttól, 5-halőgén-3-(rövid szénláncú alkil)-benző[b]fűril-csőpőrttól és 5-halőgén-3-(rövid szénláncú alkil)-benző[D]pirrőlil-csőpőrttól csak eltérő lehet. ŕ
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41619995A | 1995-04-04 | 1995-04-04 | |
| US41707595A | 1995-04-04 | 1995-04-04 | |
| US08/477,223 US5594021A (en) | 1993-05-20 | 1995-06-06 | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
| PCT/US1996/004759 WO1996031492A1 (en) | 1995-04-04 | 1996-04-04 | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9802034A2 true HUP9802034A2 (hu) | 2000-03-28 |
| HUP9802034A3 HUP9802034A3 (en) | 2000-04-28 |
Family
ID=27411089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9802034A HUP9802034A3 (en) | 1995-04-04 | 1996-04-04 | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin and use of the compounds |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP0819125B1 (hu) |
| JP (3) | JP3233642B2 (hu) |
| KR (2) | KR100359397B1 (hu) |
| CN (1) | CN1130355C (hu) |
| AT (1) | ATE243203T1 (hu) |
| AU (1) | AU711968B2 (hu) |
| CA (1) | CA2217169C (hu) |
| CZ (1) | CZ299246B6 (hu) |
| DE (2) | DE122006000068I1 (hu) |
| DK (1) | DK0819125T3 (hu) |
| EA (2) | EA199900808A1 (hu) |
| EE (1) | EE9700251A (hu) |
| ES (1) | ES2201181T3 (hu) |
| FI (1) | FI973879A0 (hu) |
| HK (1) | HK1001769A1 (hu) |
| HU (1) | HUP9802034A3 (hu) |
| NL (1) | NL300251I2 (hu) |
| NO (1) | NO315607B1 (hu) |
| NZ (2) | NZ306734A (hu) |
| OA (1) | OA10621A (hu) |
| PL (1) | PL186854B1 (hu) |
| PT (1) | PT819125E (hu) |
| TR (1) | TR199701096T1 (hu) |
| TW (1) | TW492966B (hu) |
| WO (1) | WO1996031492A1 (hu) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7326789B2 (en) | 1998-07-08 | 2008-02-05 | Sanofi-Aventis Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH09124620A (ja) | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| WO1997029747A1 (en) | 1996-02-20 | 1997-08-21 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| WO1998033781A1 (en) * | 1997-01-30 | 1998-08-06 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US5783705A (en) | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| TR200202738T2 (tr) * | 1997-04-28 | 2003-03-21 | Texas Biotechnology Corporation | Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| PL203771B1 (pl) * | 1998-07-06 | 2009-11-30 | Bristol Myers Squibb Co | Pochodna bifenylosulfonamidu jako dualny antagonista receptorów angiotensyny i endoteliny, sposób jej wytwarzania i jej zastosowanie oraz pochodna bifenylu i pochodna benzenu |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| AU6471200A (en) * | 1999-08-06 | 2001-03-05 | Takeda Chemical Industries Ltd. | Substituted aromatic-ring compounds, process for producing the same, and use |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| WO2001049289A1 (en) * | 1999-12-31 | 2001-07-12 | Texas Biotechnology Corporation | Pharmaceutical and veterinary uses of endothelin antagonists |
| DE60017195T2 (de) | 1999-12-31 | 2005-12-22 | Encysive Pharmaceuticals, Inc., Houston | Sulfonamide und ihre derivate, die die aktivität des endothelins modulieren |
| EP1533311B1 (en) * | 1999-12-31 | 2007-04-25 | Encysive Pharmaceuticals, Inc | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| GB0000625D0 (en) | 2000-01-13 | 2000-03-01 | Zeneca Ltd | Chemical compounds |
| US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
| AU2001288053A1 (en) * | 2000-09-18 | 2002-03-26 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| EP1347051A4 (en) * | 2000-12-26 | 2004-05-26 | Genox Research Inc | METHOD FOR EXAMINING AN ALLERGIC DISEASE |
| EP1486494B1 (en) * | 2002-03-15 | 2010-07-14 | TOA Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivative |
| JP4332112B2 (ja) | 2002-08-09 | 2009-09-16 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害薬 |
| CA2493575A1 (en) | 2002-08-09 | 2004-02-19 | Christopher J. Dinsmore | Tyrosine kinase inhibitors |
| SE0301888D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
| SE0301886D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use V |
| SE0301884D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use III |
| SE0301885D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use IV |
| SE0301882D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
| SE0301883D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use II |
| CA2583779C (en) * | 2004-10-14 | 2013-12-10 | Abbott Gmbh & Co. Kg | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to m0dulation of the dopamine d3 receptor |
| US7863308B2 (en) | 2007-04-10 | 2011-01-04 | Auspex Pharmaceuticals, Inc. | Substituted thiophenes |
| EP2155643B1 (en) | 2007-06-08 | 2016-08-10 | MannKind Corporation | Ire-1a inhibitors |
| CN104039781B (zh) | 2012-01-31 | 2016-08-17 | 卫材R&D管理有限公司 | 西他生坦衍生物 |
| CN107652246B (zh) * | 2017-09-25 | 2020-08-25 | 江苏乾元生物科技有限公司 | 一种3-[3-溴-2-甲基-6-(甲基磺酰基)苯基]-4,5-二氢化异噁唑的制备方法 |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| HUE064683T2 (hu) | 2019-06-18 | 2024-04-28 | Pfizer | Benzoxazol-szulfonamid származékok |
| EP3831940A1 (en) * | 2019-12-05 | 2021-06-09 | Danmarks Tekniske Universitet | Small molecule inhibitors of crispr-cas associated activity |
| CN112663077B (zh) * | 2021-01-11 | 2022-07-01 | 陕西师范大学 | 一种苯并磺内酰胺类化合物的电化学制备方法 |
| CA3217189A1 (en) | 2021-06-22 | 2022-12-29 | Alchemedicine, Inc. | Compound, endothelin a receptor antagonist and pharmaceutical composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3660383A (en) * | 1968-08-14 | 1972-05-02 | Shionogi & Co | Production of iodoisoxazole compounds |
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| TW224462B (hu) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| IL116916A (en) * | 1995-02-06 | 2000-09-28 | Bristol Myers Squibb Co | Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same |
-
1996
- 1996-04-04 AU AU55367/96A patent/AU711968B2/en not_active Ceased
- 1996-04-04 NZ NZ306734A patent/NZ306734A/en unknown
- 1996-04-04 ES ES96912600T patent/ES2201181T3/es not_active Expired - Lifetime
- 1996-04-04 DE DE1996628740 patent/DE122006000068I1/de active Pending
- 1996-04-04 TR TR97/01096T patent/TR199701096T1/xx unknown
- 1996-04-04 PT PT96912600T patent/PT819125E/pt unknown
- 1996-04-04 JP JP53052496A patent/JP3233642B2/ja not_active Expired - Lifetime
- 1996-04-04 EA EA199900808A patent/EA199900808A1/ru unknown
- 1996-04-04 DK DK96912600T patent/DK0819125T3/da active
- 1996-04-04 CZ CZ0311697A patent/CZ299246B6/cs not_active IP Right Cessation
- 1996-04-04 KR KR1019997007068A patent/KR100359397B1/ko not_active IP Right Cessation
- 1996-04-04 HU HU9802034A patent/HUP9802034A3/hu unknown
- 1996-04-04 EE EE9700251A patent/EE9700251A/xx unknown
- 1996-04-04 CA CA002217169A patent/CA2217169C/en not_active Expired - Fee Related
- 1996-04-04 EA EA199700208A patent/EA007107B1/ru not_active IP Right Cessation
- 1996-04-04 KR KR1019970707078A patent/KR100359396B1/ko not_active IP Right Cessation
- 1996-04-04 DE DE69628740T patent/DE69628740T2/de not_active Expired - Lifetime
- 1996-04-04 CN CN96193973A patent/CN1130355C/zh not_active Expired - Fee Related
- 1996-04-04 WO PCT/US1996/004759 patent/WO1996031492A1/en active IP Right Grant
- 1996-04-04 EP EP96912600A patent/EP0819125B1/en not_active Expired - Lifetime
- 1996-04-04 AT AT96912600T patent/ATE243203T1/de active
- 1996-04-04 NZ NZ500282A patent/NZ500282A/xx unknown
- 1996-04-04 EP EP00113076A patent/EP1048657A1/en not_active Withdrawn
- 1996-10-04 TW TW085112218A patent/TW492966B/zh not_active IP Right Cessation
-
1997
- 1997-10-01 PL PL96322707A patent/PL186854B1/pl not_active IP Right Cessation
- 1997-10-02 OA OA70095A patent/OA10621A/en unknown
- 1997-10-03 NO NO19974577A patent/NO315607B1/no not_active IP Right Cessation
- 1997-10-03 FI FI973879A patent/FI973879A0/fi not_active Application Discontinuation
-
1998
- 1998-02-05 HK HK98100844A patent/HK1001769A1/xx not_active IP Right Cessation
-
2001
- 2001-06-06 JP JP2001171692A patent/JP3527217B2/ja not_active Expired - Fee Related
-
2003
- 2003-09-10 JP JP2003318261A patent/JP2004043495A/ja active Pending
-
2006
- 2006-12-13 NL NL300251C patent/NL300251I2/nl unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7326789B2 (en) | 1998-07-08 | 2008-02-05 | Sanofi-Aventis Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| US8106213B2 (en) | 1998-07-08 | 2012-01-31 | Sanofi-Aventis Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| US8541410B2 (en) | 1998-07-08 | 2013-09-24 | Sanofi-Aventis Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9802034A2 (hu) | Az endotelin aktívitását módosító tienil-, furil-, pirrolil- és bifenilil-szulfonamidok, ezek származékai és alkalmazásuk | |
| HUP0001285A2 (hu) | Proteáz inhibitor hatású pirrolidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| DE69132141D1 (de) | Neuroprotective indolone und verwandte derivate | |
| HUP9700328A2 (hu) | Heteroaril-oxazolidinonok, eljárás előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények, alkalmazásuk és köztitermékeik | |
| HUP0000739A2 (hu) | Alkánszulfonil-amino-csoportot tartalmazó alkán- és heterociklusos karbonsavszármazékok, az ezeket tartalmazó gyógyszerkészítmények, valamint csontritkulás kezelésére szolgáló kombinált gyógyszerkészítmények | |
| FR2686878B1 (fr) | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. | |
| SE9100342D0 (sv) | Novel steroid esters | |
| HUP9700779A1 (hu) | Ösztrogén vegyületek, eljárás előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP9801340A1 (hu) | Triciklusos pirazolszármazékok és az azokat tartalmazó gyógyszerkészítmények | |
| HUP9901209A2 (hu) | Opioid analóg peptid vegyületek, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| FR2365553A1 (fr) | Derives amides de pentapeptides et tetrapeptides et leur utilisation comme medicaments | |
| HUP9900973A2 (hu) | Antibakteriális hatású mutilin-karbamoil-oxi-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására | |
| EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| HUP9802937A2 (hu) | Benzo[g]kinolin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk | |
| UA48937C2 (uk) | Імідазолідини, заміщені гетероциклом, спосіб їх одержання і фармацевтична композиція, що їх містить | |
| ATE196138T1 (de) | Halichondrine und verwandte verbindungen | |
| HUP9802630A2 (hu) | Királis metil-fenil-oxazolidinonok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
| HUP9601176A2 (hu) | Adhéziós receptor antagonista amidinszármazékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| FR2361901A1 (fr) | Derives de substitution de nucleotides et medicament contenant ces substances | |
| HUP0002272A2 (hu) | Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| FR2754258B1 (fr) | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant | |
| FR2445319A1 (fr) | Derives de pyridine, procedes pour leur preparation et compositions pharmaceutiques les contenant | |
| GR3025948T3 (en) | Heterocyclic alkylamines, process for their preparation and pharmaceutical compositions containing them | |
| ES469425A1 (es) | Un procedimiento para la preparacion de derivados de tiena- micina | |
| GR1001597B (el) | Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: ENCYSIVE PHARMACEUTICALS INC., US Free format text: FORMER OWNER(S): ENCYSIVE PHARMACEUTICALS INC., US; TEXAS BIOTECHNOLOGY CORPORATION, US |
|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |